Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist;Treatement de la polyarthrite rhumatoïde par l'antagoniste du recepteur de l'interleukine 1

Revue de Medecine Interne

Volumn 23, Issue 12, 2002, Pages 1006-1011

  Wendling, D ^a   Jorgensen, C ^b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

IL 1Ra; Immunotherapy; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 1; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIALOGLYCOPROTEIN;

DISEASE CONTROL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; DRUG TOLERANCE; EUROPE; EVALUATION; IMMUNOTHERAPY; INJECTION SITE; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; RADIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; CLINICAL TRIAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS;

EID: 0036907046     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00736-1     Document Type: Article

References (20)

1. Schiff MH. Role of interleukin-1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 2000;59(suppl 1):103-8.
2. Van Den Berg W. Arguments for interleukin-1 as a target in chronic arthritis. Ann Rheum Dis 2000;59(suppl 1):81-4.
3. Dayer JM. Saga de la découverte de l'IL-1 et du TNF et de leurs inhibiteurs spécifiques dans la pathogénie et dans le traitement de la polyarthrite rhumatoïde. Rev Rhum 2002;69:207-17.
4. Dayer JM, Feige U, Edwards CK, Burger D. Anti interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001;13:170-6.
5. Dinarello CA. The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. New Engl J Med 2000;343:732-4.
6. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001;30(suppl 2):1-6.
7. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001;30(suppl 2):17-20.
8. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, the IL-1Ra arthritis study group. Dose range and dose frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
9. Bresnihan B, Alvaro-Garcia JM, Cobby M, Doherty M, Domijan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
10. Nuki G, Rozman B, Pavelka K, Lookabaugh J, Musukic P. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum 1997;40 (suppl):S 224.
11. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicentre, double-blind, dose ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis, Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
12. Cunnane G, Madigan A, Murphy E, Fitzgerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001;40:62-9.
13. Bendele A, Sennello G, Mc Abee T, Frazier J, Chlipala E, Rich B. Effects of interleukin-1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats. J Rheumatol 1999;26:1225-9.
14. Bendele A, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000;43:2648-59.
15. Cohen S, Hurd E, Cush JJ, Schiff MH, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with Anakinra, a recombinant human interleukin-1 receptor antagonist, in combinaison with methoterxate, Results of a twenty four week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
16. Cohen S, Moreland LW, Cush JJ, Greenwald MW, Block JA, Shergy WJ, et al. A large, placebo controlled efficacy trial of Anakinra in patients with erosive rheumatoid arthritis diseas. Arthritis Rheum 2001;44:2946 (résumé).
17. Schiff MH, Bulpitt K, Weaver AL, Genovese MC, Cohen S, Furst D, et al. Safety of combination therapy with Anakinra and Etanercept in patients with rheumatoid arthritis. Arthritis Rheum 2001;44:S 79 (résumé).
18. Caldwell JR, Offenberg H, Furst D, Lam NP, Jayne G, Joh T, et al. A phase I safety study of combination treatment with pegylated soluble tumor necrosis factor receptor type I and Anakinra in patients with rheumatoid arthritis. Arthritis Rheum 2001;44:S 370 (résumé).
19. Fleishmann R, Schechtman J, Bennett R, Handel M, Burmester GR, Tesser J, et al. A safety trial of Anakinra: Recombinant interleukin-1 receptor antagonist (IL-1RA), in a large, placebo-controlled heterogeneous population of patients with rhematoid arthritis. Arthritis Rheum 2001;44:S 84 (résumé).
20. Van Den Berg WB. Uncoupling of inflammation and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001;30(suppl 2):7-16.